

**2025** YEAR IN  
REVIEW

**Welcome from  
AVAC's Board  
President &  
Executive Director**

**Impact  
by the  
Numbers**

**Year  
in  
Review**

**Our Vision  
for the  
Year Ahead**

**AVAC  
in the  
News**

**AVAC  
Resources**



# WELCOME FROM AVAC'S BOARD PRESIDENT & EXECUTIVE DIRECTOR



**Blair Hanewall**  
Board President

2025 underscored the vital role that AVAC plays in the global health ecosystem, and why our work and our partnerships have never been more essential.

Long-standing commitments to HIV and global health were rolled back; politics interfered in science and service delivery and misinformation and distrust were at an all-time high. Yet, prevention science persevered, offering real promise for the future through new prevention options and expanded choices to end the epidemic.

In this moment of crisis and possibility, AVAC did what it has done for 30 years: *We showed up, spoke out and worked with partners to push the field forward. This Year in Review captures how AVAC navigated 2025 and the impact of our work.*

When unconscionable cuts to foreign aid threatened global HIV prevention programs, AVAC was among the first to act—using every tool available, from litigation to data tracking to policy advocacy to fight the cuts. Together with partners, we helped protect hundreds of millions of dollars for HIV prevention.

We led and supported a broad, coordinated response to defend HIV research. Through policy engagement, tracking new developments via *Global Health Watch* and high-visibility actions like the Save HIV Research marathon, AVAC mobilized advocates, researchers, policymakers and communities to make the case for science, helping to keep research funding and scientific integrity on the agenda at a critical moment.

Through it all, AVAC delivered the most trusted HIV prevention data, tools and analysis, from pipeline tracking and infographics to real-time monitoring of prevention access and rollout; advanced the conversations on prevention and

rolled out an updated *People's Research Agenda*, grounded in the reality that science only matters if people support it, can access, choose and use it; and applied our core policy, advocacy and communications competencies in HIV prevention to expanded work on HIV cure research and sexually transmitted infections.

This year was also a pivotal one for injectable lenacapavir (LEN) for PrEP. Years of groundwork, rooted in our decades-long work on PrEP, ensured AVAC was there to help the field move faster and more equitably than ever before. We supported country and community leadership across Africa, engaged ministries of health and other key stakeholders and delivered clear, accessible information to keep LEN rollout momentum aligned with equity.

Throughout, AVAC's model of partnership and shared leadership remained central. Our work is powered by relationships with advocates, researchers, implementers and community leaders around the world. In a year when advocacy was more necessary (and harder) than ever, these partnerships were the bedrock of our actions.

This report highlights AVAC's role as a trusted voice, a translator of science and a catalyst for action and advocacy. It reflects an organization ready for the future: supporting African leadership, strengthening bridges from R&D to delivery and preparing for a new chapter as we move forward into our fourth decade as an organization.

None of this work happens without you. We are deeply grateful to our donors, partners and allies who continue to invest in AVAC and our shared goals. Your support makes it possible to respond rapidly in moments of crisis and to stay focused on what matters most.

As we look ahead, challenges remain, but so do opportunities. The science is strong, new options are in the pipeline, and with smart analysis, rigorous science, good policies and global partnership, progress is within reach.

Thank you for being part of this work, and for standing with AVAC in this defining year.

Onwards

*A special thanks to our **donors**, who make this critical work possible through their sustained support. To our **partners**, thank you for the constant solidarity and collaboration that makes our collective work matter.*



# ↑ IMPACT BY THE NUMBERS

From accelerating HIV prevention breakthroughs to protecting global health investments, these numbers reflect our impact in action: how our evidence-based advocacy, research engagement, policy influence and partnerships translated into measurable progress across HIV, STI and global health priorities.

## 10,000 participants

reached globally through the **24-Hour Marathon to Save AIDS Research**, bringing critical attention to HIV research and the risk of funding cuts



## 90,000 visitors

to the **PrEPWatch website**, featuring the most comprehensive **global PrEP initiation dataset** and access to over 1,000 resources



## 12 ministries of health

in early lenacapavir (LEN) adopter countries supported in **planning for roll-out** and **7 civil society organizations** supported to **advance civil society engagement** in LEN roll-out, creating a multi-pronged approach for technical assistance that prioritized community needs, country leadership and equity

## 61 trial sites

launched recruitment for the **MK-8527 Phase 3 trials** of a monthly oral PrEP pill, backed by **AVAC's Good Participatory Practice guidelines** and community engagement, informed and guided by AVAC and partners, throughout the design and implementation process

## \$2 billion

in frozen foreign aid funds **paid back to implementing partners** for completed work as part of **AVAC's lawsuit** against the US government

**Judge orders Trump to pay USAID partners, rejects 'unbounded' power**

## \$400 million

in PEPFAR funds **saved from Congressional rescissions** through successful advocacy by global health advocates, including AVAC and partners



## 6 LEN milestones

achieved in the first 15 months following efficacy results, **5 years faster than oral PrEP** and **2 years faster than CAB**, facilitated by AVAC's work to produce evidence-based materials and coordinate stakeholder communication and joint decision-making

## 48 issues

of **Global Health Watch** published in 2025, serving as the field's go-to source for updates on US policy and its impact on global health and research



## 93 research

products tracked across the R&D pipeline as part of the updated **People's Research Agenda** to advance community-driven priorities in HIV prevention research




## 2,800 subscribers

To **The Choice Agenda**, a global forum for the latest HIV prevention news; TCA hosted 55 webinars since 2022, reaching thousands more



# → YEAR IN REVIEW

Throughout a tumultuous year, AVAC fought for science, research and equity—and secured important wins that helped advance HIV programs, biomedical research and global health generally. These five stories outline important achievements in the following areas:



Together, these demonstrate AVAC’s unwavering commitment to ending the HIV/AIDS epidemic and advancing global health equity and the collective impact of the organization and its partners.

# The Fight to Save HIV Research

A new US Administration took office in January 2025 and immediately moved to dismantle public health infrastructure in the US and around the world, including massive cuts to HIV and other global infectious disease research and widespread misinformation campaigns to discredit and undermine scientific knowledge, evidence and vaccine confidence. Since day one, AVAC has served as a leader in standing up against this administration, bringing critical visibility to why investments in HIV services and research—and scientific research as a whole—matters.


AVAC worked with global civil society partners to mobilize leading voices in research; strengthen advocacy skills through **teach-ins**, **tools** and **resources**; **educate policy makers**; conduct direct advocacy with members of the administration; make public comments; and **disseminate timely and accurate information** to track the impact of US government cuts to HIV and STI research. AVAC's **Research Matters series**, in partnership with the Treatment Action Group (TAG) and the HIV Medicine Association (HIVMA), provided briefings for researchers and policymakers and a toolkit of messages and advocacy guides for action to save research funding. Initiatives with allies—Global Health Technologies Coalition (GHTC), FAPP Research Work Group, Save HIV Funding Campaign (SHF) and others—focused on pushing policymakers to preserve funding through legislative educational sessions.



**Dr. Gregg Gonsalves**, a long-active activist and AIDS researcher at the Yale University School of Public Health, and co-creator with AVAC of the 24-hour Marathon to Save AIDS Research on the need to sustain HIV research

## THE COST OF CUTTING HIV RESEARCH

NIH terminated 191 HIV-specific grants in 2025, slashing over \$200 million from key HIV prevention research areas<sup>1</sup>



<sup>1</sup>Grants may cover more than one research area, therefore the total across categories shown here exceeds \$200 million in total funding lost

AVAC's analysis of the impact of NIH funding cuts across key areas of HIV prevention research.



# Protecting Global Prevention Gains


In 2025, AVAC was on the front lines of protecting global gains against the new administration’s illegal and unconscionable cuts to US foreign assistance, including major HIV programs and USAID. On February 10, 2025, AVAC and the Journalism Development Network (JDN), represented by Public Citizen’s Litigation Group, sued the President, the State Department, the US Agency for International Development (USAID) and others, seeking emergency relief from an Executive Order that inhumanely froze all funding for foreign assistance.

The freeze halted the life-saving work of organizations across the globe, contributed to thousands of lives lost and cost thousands of American jobs and hundreds of thousands of jobs globally. The freeze forced AVAC to abruptly stop CASPR, a coalition of African civil society organizations that supports research on HIV prevention and provides resources for local communities. AVAC’s lawyer at Public Citizen, Lauren Bateman, said, “The Trump administration’s freeze on foreign assistance funding is dangerous and illegal. When programs are abruptly shuttered, the impacts are felt throughout the world—with the most vulnerable people bearing the deadliest impact.”

AVAC and JDN, along with the Global Health Council and additional plaintiffs in a companion lawsuit, challenged both the suspension of funds as well as the legality of the termination of grants and funding. In court filings, the government argued that these decisions fell under the administration’s foreign policy purview, and disregarded restraining orders and directives from the courts to reinstate funds. Following a



AVAC’s **Mitchell Warren** speaks with CNN about the consequences of the US not commemorating World AIDS Day.



The devastating impacts of US foreign assistance cuts on global PrEP delivery.

series of decisions, appeals and stays, on March 5 the Supreme Court ruled in our favor that the Administration must release up to \$2 billion in frozen foreign assistance funding. This ruling was an important win and resulted in back payment to implementing partners and contractors for work completed prior to the freeze.

The additional issues at stake—the unlawful “blanket suspension”, cancellation of grants and contracts, and the executive branch “impounding” funds that Congress appropriated—continued to be reviewed by the courts. Critically, if appropriated foreign assistance funds were not spent by September 30, they would be lost. On September 26, the Supreme Court granted the administration’s request to stay a district court injunction in our case that required the administration to obligate \$4 billion of foreign assistance funds before they expire on September 30—as required by law—and allowing those life-saving funds to go unspent. The case is currently on hold, pending the outcome of other cases that may impact the ruling.


At the same time, as the field’s go-to source for tracking and analysis, AVAC rapidly turned to tracking the impact of the stop work orders on **HIV research, PrEP delivery and STI research and programming**, calling on the US Congress to protect and restore funding. As a result of advocacy leadership by AVAC and partners, along with coordinated messaging through the Save HIV Funding campaign, the US Senate amended the president’s proposed rescissions package to remove a \$400 million cut to already appropriated fiscal year 2025 funding for PEPFAR. The amendment, passed with bipartisan support, was an unexpected win amid escalating attacks on global health. Additionally, the US recommitted to rolling out lenacapavir (LEN) under PEPFAR (albeit without critical funding for LEN in South Africa), and restored funding for **Gavi, the Vaccine Alliance**, was included in recent appropriations bills—reflecting moves by Congress to protect critical foreign assistance funding.



*“The fight against HIV is a fight for humanity, and it must continue. Now more than ever, we must raise our voices to protect these vital resources and advocate for an HIV response that prioritizes health equity and social justice.”*

**John Meade Jr.** ←

Senior Program Manager: Policy



A map showing the impact of PEPFAR stop work orders on global PrEP services, with the majority being reduced.

*“We cannot cede ground gained against HIV and other global health threats out of fear or paralysis in the face of these reckless actions. It is imperative to hold this administration responsible. And it’s imperative to invest in global health and sustain the gains in HIV.”*

**Mitchell Warren** ←

AVAC Executive Director

# Advancing Research, Redefining Choice

Diminished funding for research and foreign assistance requires sharper priorities and smarter investments to develop and deliver a wide range of products that meet diverse needs. Given the new reality of the HIV response, AVAC and partners also recognize that the conversation around choice must be redefined, and research pipelines must be prioritized and optimized accordingly.

In 2025, AVAC released an updated *People's Research Agenda* (PRA) to reflect this context. Created in 2024 with global advocates and communities, the PRA provides a people-centered framework for equitable and accelerated R&D and product introduction. Dr. Jeanne Marrazzo, then-Director of the National Institute of Allergy and Infectious Disease (NIAID), endorsed the PRA at its 2024 launch, coining it a “manifesto for putting community voices front and center.” The 2025 PRA update reflects a critical review of the HIV prevention research pipeline, especially given shifting US political support, emphasizing a strict balance of R&D that is optimized for maximum impact on the epidemic. Its interactive features, including a dashboard for tracking and advocating for HIV prevention R&D, a real-time clinical trials tracker and an action agenda, make it a core tool for advocates, researchers and funders in the current landscape.



*“Thanks to the entire AVAC team for the platforms, the timely updates and the simplified messages that gave us a voice and kept us informed. Most importantly, thank you for continuously empowering the community with the knowledge and resources needed to contribute meaningfully, especially at this pivotal moment for HIV prevention.”*

**Adaobi Olisa**

Root to Rise and AVAC Clinical Trial Design Academy member



A map of EXPRESSIVE trial sites—a phase 3 trial of MK-8527, Merck's monthly PrEP pill.



*“We have more HIV prevention tools than ever before in history, but we know that innovation alone does not create impact. We must continue to develop products that fill gaps and deliver them in a way that offers authentic choice.”*

**Grace Kumwenda**

AVAC’s Regional Program Manager for Research Engagement

As a trusted ally to community and researchers alike, AVAC also played a leading role in advancing Good Participatory Practice (GPP) in the research program for developing monthly oral MK-8527 PrEP, with support from the Gates Foundation. AVAC engaged nearly 100 advocates from around the world through various engagement platforms and consultations to ensure that trial design, conduct and access plans were designed with community input. As the **efficacy program launched**, advocates **praised the program’s commitment to community engagement** and the exciting opportunity MK-8527 offers for expanding choice.

Similarly, AVAC continued engagement and advocacy in the HIV cure research field. As the community engagement partner to three Martin Delaney Collaboratories and the African HIV Cure Consortium, AVAC drove engagement at local, national and global levels. Through partnerships with African-based civil society groups, cure research was prioritized in country strategic plans in both Malawi and Uganda—a significant win, given the increased need for country commitments to national HIV responses in the face of diminished US support. AVAC also expanded a global network of cure advocates by replicating the African-focused Cure Advocacy Academies (implemented in partnership with IAS) in the US with the first ever US Cure Advocacy Academy.

Throughout 2025, AVAC continued to be a critical resource for the field, disseminating **infographics**, quarterly **Px Wire** updates and **tools** to help partners stay abreast of the evolving research pipeline and introduction status of oral PrEP, the DVR, CAB and LEN. From international conferences to community meetings, AVAC resources were cited widely, affirming AVAC as a go-to source for accurate HIV prevention information and a catalyst for strong advocacy.

## HIV PREVENTION PIPELINE: PRODUCTS TO WATCH

PRECLINICAL	PHASE I	PHASE II	PHASE III	IMPLEMENTATION
<p><b>Hundreds of...</b></p> <ul style="list-style-type: none"> <li>ARV-Based</li> <li>MPTs</li> <li>Vaccine candidates</li> <li>bNAbs candidates</li> </ul>	<ul style="list-style-type: none"> <li>3-Monthly DPV + LNG</li> <li>On-Demand TAF + EVG</li> <li>Vaccine candidates</li> <li>Combo bNAb candidates</li> </ul>	<ul style="list-style-type: none"> <li>Event-Driven FTC/TAF</li> <li>On-Demand TFV</li> <li>Combo bNAb candidates</li> </ul>	<ul style="list-style-type: none"> <li>Monthly MK-8527</li> </ul>	<ul style="list-style-type: none"> <li>Daily TDF/FTC</li> <li>Daily FTC/TAF</li> <li>2-Monthly CAB</li> <li>6-Monthly LEN</li> <li>Monthly DPV</li> </ul>
<p>The US Govt’s shut down of USAID ended six critical HIV research projects. With MATRIX, the field lost an important effort to develop diverse, on-demand, and multi-purpose products, especially for young women. The ADVANCE and BRILLIANT projects were researching a range of vaccine candidates while also building African-led research agendas.</p> <ul style="list-style-type: none"> <li>Long-acting implants</li> <li>Multi-purpose vaginal ring</li> <li>Vaginal &amp; mucosal inserts</li> <li>Vaginal film</li> <li>Vaccines</li> </ul>		<p><b>BIO-EQUIVALENCE</b></p> <ul style="list-style-type: none"> <li>4-Monthly CAB</li> <li>12-Monthly LEN</li> <li>3-Monthly DPV</li> <li>Daily DPP</li> </ul>		

Credit: AVAC

The People’s Research Agenda high-level look at the HIV prevention pipeline.

# Getting LEN Rollout Right

In June 2025, the US Food & Drug Administration’s approval of injectable lenacapavir (LEN) provided a much-needed boost for HIV prevention, particularly given the strength of the science and the simultaneous global disruption of HIV research and programs by the US government.

Drawing on three decades of experience and expertise from earlier PrEP rollouts, AVAC served as a leading voice for access and equity, demanding that “scientific progress only matters if innovation actually reaches people. LEN for PrEP is poised to re-shape the HIV response, but only if approval is accompanied by bold, strategic, effective and equitable rollout that reaches the populations that need access.”

AVAC’s efforts helped lay the groundwork for LEN to move faster and more equitably through the pipeline and into roll-out. In 2025, AVAC strengthened the partnerships, coordination and evidence base needed for rapid and inclusive LEN scale-up. Six key LEN milestones were achieved in record




*“Experience in HIV prevention shows that products succeed when countries lead. African leadership is essential for turning lenacapavir from a scientific breakthrough into a real public health breakthrough. This leadership ensures that innovation translates into meaningful and equitable impact for the communities who need it most.”*

Wawira Nyagah

AVAC Director of Product Introduction and Access and incoming Executive Director of the Kenya-based Health Market Access Bridge

## SOURCE OF LENACAPAVIR FOR PrEP SUPPLY TO EARLY ADOPTER COUNTRIES


PEPFAR and Global Fund are supporting 22 countries with early access to programmatic supply of LEN, with some supply already arriving in country in Q4 2025 and the rest expected to arrive by end of Q1 2026; Unitaid, the Gates Foundation and Gilead are supporting 10 implementation science projects in 4 countries.



Map showing sources of LEN for PrEP supply across early adopter countries.


### POTENTIAL MARKET OF LEN FOR PrEP

The top 16 PrEP markets, based on 2024 oral PrEP initiations and the possible 2026 injectable market, assuming 60% of new PrEP users choose an injectable, as seen in implementation studies



Top 16 countries with the largest projected markets for long-acting injectable PrEP

### PREPARING FOR LEN: LEARNING LESSONS, ACCELERATING ACCESS, REDUCING TIME TO IMPACT



Comparison of LEN milestones after efficacy results, with oral PrEP, DVR and CAB

time; what took more than five years for oral PrEP and two years for injectable CAB following the publication of efficacy results, took just a year for LEN—including multiple **regulatory approvals**, WHO recommendation and pre-qualification, and initial **product launch**.

Over the years, AVAC has served as a translator, catalyst and advocate for the field, accelerating PrEP product development and introduction. AVAC’s online **PrEPWatch** clearinghouse tracks global progress, challenges and accountability across PrEP research, access and rollout; AVAC convenes stakeholders to advance global conversations on product development and delivery, and to ensure community advocates have a central voice in decision-making spaces. AVAC’s LEN resources were among the most sought-after and referenced documents in the field—among advocates, Ministries of Health, researchers and implementers—providing evidence and analysis for fieldwide decision-making during LEN rollout planning.

AVAC’s leadership resulted in the creation of sustainable models for collaboration, including the **Coalition to Accelerate Access to Long-Acting PrEP**, among normative agencies, funders, civil society, ministries of health and implementers, fostering early national action plans, stronger donor alignment and inclusive strategies for faster LEN rollout. Working closely with country-level stakeholders, AVAC established a Community of Practice for ministries of health as a space for regional learning, donor dialogue and problem-solving. AVAC supported civil society partners in early adopter countries, centering civil society’s leadership, providing a structured foundation for national stakeholder meetings and ensuring accountability and swifter action toward LEN introduction at the country level.

AVAC served as the global source for evidence-based materials to support LEN introduction, including infographics, analysis and guides covering regulatory approvals, procurement and pricing updates, and providing key advocacy messages to accelerate scale-up. By producing and sharing timely, accessible information, this work ensured field-wide coordination and enabled more intentional, informed civil society engagement in planning for LEN rollout.




The power of partnership is the heart of HIV advocacy. For decades, AVAC has built partnerships based on a shared vision of African-led advocacy for global health to ensure critical research continues, products move more quickly through the pipeline and access is more equitable across communities. In 2025, AVAC’s work with partners reflected that vision, advancing the field in critical ways through collaborative efforts.

AVAC has worked to re-center advocacy leadership in Africa through decades of global collaboration and investment: the AVAC Advocacy Fellows program mentored nearly 100 Fellows over 18 years, achieved powerful advocacy wins and built a new generation of civil society advocates. In 2025, the latest group of Fellows advanced HIV cure research, scaled up U=U, expanded access to prevention products and services, and strengthened pandemic prevention efforts. As civil society organizations carry mentorship work into 2026 and beyond, the future of leadership in HIV research and prevention advocacy is stronger, more sustainable and closely aligned with community needs.

In 2025, the Coalition to Build Momentum, Power, Activism, Strategy and Solidarity (COMPASS)-Africa, a global coalition



**Yvette Raphael**, Executive Director of APHA, speaking at the World Health Summit highlighting the importance of community-led responses in effective HIV prevention advocacy.




2024–2025 Advocacy Fellows cohort (from top, left): **Bahati Thomas Haule, Mokone Rantsoeleba, Elina Mwasinga, Samuel Anyula Gorigo, Ezra Meme, Rhoda Msiska, and Pamela Fuzile**

focused on influencing HIV policy decisions, programs and funding, completed the first year of leadership under an African-led Secretariat—Pangaea Zimbabwe. This **transition from AVAC to Pangaea**, based on a foundational commitment from AVAC to power-sharing and a multi-year transition plan with coordination and buy-in from across the coalition, carries forward the coalition’s vision of regional leadership and sustainability of advocacy movements. Similarly, over nine years of impactful collaboration and advocacy before it was halted in February 2025 during the foreign assistance freeze, the **Coalition to Accelerate and Support Prevention Research (CASPR)**—an African-led advocacy coalition focused on advancing biomedical HIV prevention research and access—contributed to increased community engagement in research and strengthened African advocacy leadership in the HIV response.

AVAC and partners, built on the foundational work of the Fellows program, COMPASS and CASPR, continue to advance and realize this shared vision of partnership and the future of African-led advocacy. A coalition of partners began to jointly establish a framework for this future, focusing on building an **advocacy institute** to sustain HIV prevention advocacy leadership in Africa. In 2026, this coalition will focus on building out this model, identifying the most effective ways to collaborate and advance a shared vision for African-led advocacy for global health.

### AVAC FELLOWS ALUMNI LEADERSHIP IN AFRICA

The AVAC Advocacy Fellows Program has supported 92 Fellows from Africa since 2009. Twenty Fellows Alumni have since founded or are currently leading an organization that partners with AVAC to impact public health



Map showing AVAC Fellow Alumni representation in 13 African countries, with alumni founding or leading 17 organizations in seven countries.



*“Investing in African-led advocacy has never been more important. HIV prevention advocates came together to create an institute that meets the moment—ensuring advocates build a new global health architecture with communities at the center, and that breakthroughs like LEN turn into real-world impact for communities who need them most.”*

Navita Jain

AVAC Senior Program Manager

# → OUR VISION FOR THE YEAR AHEAD

With immense challenges and historic opportunities ahead, we recommit to advancing our collective work in the months to come.

2026 will be marked by AVAC's commitment to:

- 
- 1** Rethink and rebuild an architecture for global health that acknowledges the changing landscape and insists on equity while centering advocacy and communities.
  - 2** Amplify and drive the call for effective and equitable research & development to advance a pipeline that is optimized for maximum impact toward an ultimate end to HIV.
  - 3** Accelerate speed, scale and equity in access to existing long-acting PrEP options.
  - 4** Champion science, evidence-based policies and investments in HIV, Cure and STI research.
  - 5** Monitor, analyze and document the impact of policies, programs and investments to inform decision-making and field-wide strategies.
  - 6** Empower the field with real-time updates that track and translate the research pipeline, from basic science to product rollout.

Working together, we can meet the moment with a bold agenda to bring HIV prevention and equity in global health to everyone who needs it.

# AVAC IN THE NEWS

Throughout the year, AVAC staff were featured across global media platforms. From interviews to opinion pieces, AVAC's expertise helped shape public dialogue and conversations around HIV prevention, foreign assistance, and much more.

**The New York Times**  
February 8, 2025  
**With Aid Cutoff, Trump Halts Agency's Legacy of 'Acting With Humanity'**  
[CLICK TO READ FULL ARTICLE](#)

**The New York Times**  
February 11, 2025  
**Two Nonprofits Sue Over Trump's Freeze on Foreign Aid**  
[CLICK TO READ FULL ARTICLE](#)

**devex**  
Do Good. Do It Well.™  
February 26, 2025  
**Nearly 10,000 Awards Cut from USAID, State Department**  
[CLICK TO READ FULL ARTICLE](#)

**devex**  
Do Good. Do It Well.™  
March 5, 2025  
**Supreme Court Hands USAID Partners A Win**  
[CLICK TO READ FULL ARTICLE](#)

**TheBody**  
April 7, 2025  
**US HIV Researchers Reel at Widespread Cancellations to Domestic Funding**  
[CLICK TO READ FULL ARTICLE](#)

**devex**  
Do Good. Do It Well.™  
May 29, 2025  
**Opinion: The US Legacy in HIV is Unraveling**  
[CLICK TO READ FULL ARTICLE](#)

**The New York Times**  
June 18, 2025  
**Regulators Approve A Twice-Yearly Shot to Prevent H.I.V. Infection**  
[CLICK TO READ FULL ARTICLE](#)

**THE NEW YORKER 100**  
June 24, 2025  
**The Drug That Could Revolutionize The Fight Against H.I.V.**  
[CLICK TO READ FULL ARTICLE](#)

**spotlight**  
In-depth, public interest health journalism  
July 25, 2025  
**IAS2025: Findings Give Hope For Monthly HIV Prevention Pill**  
[CLICK TO READ FULL ARTICLE](#)

**TheBodyPro**  
September 2, 2025  
**The Real-World Impact of Defunding STI Research**  
[CLICK TO READ FULL ARTICLE](#)

**POZ**  
September 15, 2025  
**Watch "24 Hours to Save AIDS Research," An Online Marathon to Highlight HIV Research Advances**  
[CLICK TO READ FULL ARTICLE](#)

**gay city news**  
September 16, 2025  
**'HIV Unwrapped' Combines Science and Style for New York Fashion Week**  
[CLICK TO READ FULL ARTICLE](#)

**BMJ Journals**  
Sexually Transmitted Infections  
October 2025  
**'Self-testing' Versus 'Self-collection': The Critical Role of Consistent Language in the Field Of STI Diagnostics**  
[CLICK TO READ FULL ARTICLE](#)

**HEALTHBEAT**  
October 2, 2025  
**Deal to Lower Price for New HIV Prevention Shot is 'Huge Moment of Hope' in Global Health**  
[CLICK TO READ FULL ARTICLE](#)

**npr**  
November 18, 2025  
**A 'Breakthrough' Drug to Prevent HIV, An 'Unprecedented' Rollout**  
[CLICK TO READ FULL ARTICLE](#)

**The Washington Post**  
November 18, 2025  
**Trump HIV Prevention Plan Shuts Out South Africa—The Nation Most Affected**  
[CLICK TO READ FULL ARTICLE](#)

**Vox**  
November 21, 2025  
**The US is fast-tracking this important HIV drug—for everyone except South Africa**  
[CLICK TO READ FULL ARTICLE](#)

**thebmj**  
November 27, 2025  
**"Miraculous" HIV Drug To Be Rolled Out After Overcoming AID Cuts Threat**  
[CLICK TO READ FULL ARTICLE](#)

**Think Global Health**  
December 1, 2025  
**Lenacapavir Can Transform HIV Prevention—If Countries Support Access**  
[CLICK TO READ FULL ARTICLE](#)

**PA**  
December 11, 2025  
**From Promise to Programs—How to Ensure PrEP Science is Translated Into Global Impact**  
[CLICK TO READ FULL ARTICLE](#)



Throughout the year, AVAC was a leading, public voice in fighting the administration and promoting the need for HIV prevention research and access.



February 27, 2025 — abc NEWS

**HEAD OF AIDS ADVOCACY PROGRAM ON SUIT AGAINST TRUMP ADMINISTRATION**

ABC News' Phil Lipof spoke with Mitchell Warren about the organization's lawsuit against the Trump administration over the funding freeze.



March 26, 2025 — DEMOCRACY NOW!

**"LIFT THE FREEZE": HIV/AIDS ADVOCATES WIN SUPREME COURT VICTORY IN FIGHT OVER TRUMP FOREIGN ASSISTANCE CUTS**

Mitchell Warren and Public Citizen Litigation Group's Nicolas Sansone spoke with Amy Goodman in a televised interview about the foreign assistance freeze case and the impact of the new administration's orders on global health.



July 1, 2025 — PBS NEWS

**HOW A NEW TWICE-YEARLY DRUG IS PROMPTING HOPES OF CURBING HIV CASES**

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. William Brangham and Mitchell Warren discussed the promise of the newly approved LEN for PrEP at changing to course of the AIDS epidemic.



December 1, 2025 — abc NEWS

**PRESIDENTIAL HIV COUNCIL WARNS PROPOSED CUTS COULD REVERSE DECADES OF PROGRESS**

Mitchell Warren discussed the potential impact of the Trump administration's proposed cuts.

AVAC trackers, newsletters, graphics and other tools were critical assets for stakeholders advancing HIV prevention, cure and STI initiatives. This snapshot features AVAC resources produced this year, and how they were used to strengthen the HIV prevention ecosystem. AVAC's full repository of resources can be found on our [website](#), on [PrEPWatch](#), and on [STIWatch](#).



## The Choice Agenda

A global forum for advocacy on the latest in HIV prevention research



## An "Innovation Pile Up" in Next Gen PrEP

One of AVAC's newest infographics, forecasting the future of PrEP



## Injectable Lenacapavir for PrEP

The field's go to source for information on LEN rollout



## Impact Trackers

Real-time tracking of the cuts to research, global health and HIV commitments



## Getting PrEP Rollout Right This Time

A synthesis of lessons from early PrEP rollout that is informing LEN scale-up




## STIWatch Quarterly Newsletter

A curated quarterly roundup of key developments in STI prevention



## HIV Prevention Pipeline Tracker

This continuously updated database tracks HIV prevention products and clinical trials to watch



## Cure in the Spotlight


Highlighting the impact of AVAC supported HIV cure champions



Wawira Nyagah, AVAC and Health Market Access Bridge, leads **ICASA 2025** satellite "Innovating to Scale PrEP in a New Reality."



Dr. Jeanne Marrazzo, CEO of IDSA, uses AVAC infographics at the closing lecture of the **STI & HIV 2025 World Congress meeting**.



Dr. Nyaradzo Mgodi, HPTN PI, uses AVAC infographics to emphasize the continued need for an HIV vaccine in an **IAS 2025 session**.



Dr. Anthony Fauci highlighted AVAC during a **NASTAD-GWU School of Medicine and Health Sciences summit** on how clinicians can help end the HIV epidemic.